Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.
2.

Skin-derived precursor cells undergo substrate-dependent galvanotaxis that can be modified by neighbouring cells.

Iwasa SN, Popovic MR, Morshead CM.

Stem Cell Res. 2018 Aug;31:95-101. doi: 10.1016/j.scr.2018.07.019. Epub 2018 Jul 19.

3.

A dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Jul 24. doi: 10.1111/cas.13750. [Epub ahead of print]

4.

Retrospective Analyses of Systemic Chemotherapy and Cytoreductive Surgery for Patients with Ovarian Metastases from Colorectal Cancer: A Single-Center Experience.

Sekine K, Hamaguchi T, Shoji H, Takashima A, Honma Y, Iwasa S, Kato K, Takahashi K, Kato T, Kanemitsu Y, Boku N.

Oncology. 2018;95(4):220-228. doi: 10.1159/000489665. Epub 2018 Jul 20.

PMID:
30032147
5.

Direct Catalytic Asymmetric Cyclopropylphosphonation Reactions of N,N-Dialkyl Groups of Aniline Derivatives by Ru(II)-Pheox Complex.

Le CTL, Ozaki S, Chanthamath S, Shibatomi K, Iwasa S.

Org Lett. 2018 Aug 3;20(15):4490-4494. doi: 10.1021/acs.orglett.8b01788. Epub 2018 Jul 11.

PMID:
29992821
6.

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y.

Br J Radiol. 2018 Sep;91(1089):20180259. doi: 10.1259/bjr.20180259. Epub 2018 Jun 27.

PMID:
29916721
7.

Development of an Immunosensor Based on Surface Plasmon Resonance for Simultaneous Residue Analysis of Three Pesticides -Boscalid, Clothianidin, and Nitenpyram- in Vegetables.

Hirakawa Y, Yamasaki T, Harada A, Iwasa S, Narita H, Miyake S.

Anal Sci. 2018;34(5):533-539. doi: 10.2116/analsci.17P487.

8.

Highly enantioselective synthesis of trifluoromethyl cyclopropanes by using Ru(ii)-Pheox catalysts.

Kotozaki M, Chanthamath S, Fujii T, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2018 May 15;54(40):5110-5113. doi: 10.1039/c8cc02286k.

PMID:
29717307
9.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.

Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.

PMID:
29555258
10.

Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K.

Int J Clin Oncol. 2018 Aug;23(4):652-658. doi: 10.1007/s10147-018-1258-7. Epub 2018 Mar 8.

PMID:
29520523
11.

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.

Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Int J Clin Oncol. 2018 Jun;23(3):466-472. doi: 10.1007/s10147-018-1239-x. Epub 2018 Jan 20.

PMID:
29353337
12.

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K.

Cancer Sci. 2018 Mar;109(3):785-793. doi: 10.1111/cas.13481. Epub 2018 Feb 15.

13.

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.

Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T.

Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10.

14.

A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).

Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y.

Clin Colorectal Cancer. 2018 Mar;17(1):e83-e89. doi: 10.1016/j.clcc.2017.10.004. Epub 2017 Oct 16.

PMID:
29169974
15.

Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.

Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N.

Oncology. 2018;94(1):47-54. doi: 10.1159/000480515. Epub 2017 Oct 28.

PMID:
29080886
16.

Highly stereoselective cyclopropanation of various olefins with diazosulfones catalyzed by Ru(ii)-Pheox complexes.

Kotozaki M, Chanthamath S, Fujisawa I, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2017 Nov 9;53(90):12193-12196. doi: 10.1039/c7cc05951e.

PMID:
29072719
17.

Synthesis, Crystal Structure, and Photoluminescent Properties of 3,3',4,4'-Tetraethyl-5,5'-divinyl-2,2'-bipyrrole Derivatives.

Okawara T, Kawano R, Morita H, Finkelstein A, Toyofuku R, Matsumoto K, Takehara K, Nagamura T, Iwasa S, Kumar S.

Molecules. 2017 Oct 26;22(11). pii: E1816. doi: 10.3390/molecules22111816.

18.

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.

Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.

Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16.

PMID:
29039073
19.

Abstracts and Workshops 7th National Spinal Cord Injury Conference November 9 - 11, 2017 Fallsview Casino Resort Niagara Falls, Ontario, Canada.

Shojaei MH, Alavinia M, Craven BC, Cheng CL, Plashkes T, Shen T, Fallah N, Humphreys S, O'Connell C, Linassi AG, Ho C, Short C, Ethans K, Charbonneau R, Paquet J, Noonan VK, Furlan JC, Fehlings MG, Craven BC, Likitlersuang J, Sumitro E, Kalsi-Ryan S, Zariffa J, Wolfe D, Cornell S, Gagliardi J, Marrocco S, Rivers CS, Fallah NN, Noonan VK, Whitehurst D, Schwartz C, Finkelstein J, Craven BC, Ethans K, O'Connell C, Truchon C, Ho C, Linassi AG, Short C, Tsai E, Drew B, Ahn H, Dvorak MF, Paquet J, Fehlings MG, Noreau L, Lenz K, Bailey KA, Allison D, Ditor D, Baron J, Tomasone J, Curran D, Miller T, Grimshaw J, Moineau B, Alizadeh-Meghrazi M, Stefan G, Masani K, Popovic MR, Sumitro E, Likitlersuang J, Kalsi-Ryan S, Zariffa J, Garcia-Garcia MG, Marquez-Chin C, Popovic MR, Furlan JC, Gulasingam S, Craven BC, Furlan JC, Gulasingam S, Craven BC, Khan A, Pujol C, Laylor M, Unic N, Pakosh M, Musselman K, Brisbois LM, Catharine Craven B, Verrier MC, Jones MK, O'Shea R, Valika S, Holtz K, Szefer E, Noonan V, Kwon B, Mills P, Morin C, Harris A, Cheng C, Aspinall A, Plashkes T, Noonan VK, Chan K, Verrier MC, Craven BC, Alappat C, Flett HM, Furlan JC, Musselman KE, Milligan J, Hillier LM, Bauman C, Donaldson L, Lee J, Milligan J, Lee J, Hillier LM, Slonim K, Wolfe D, Sleeth L, Jeske S, Kras-Dupuis A, Marrocco S, McRae S, Flett H, Mokry J, Zee J, Bayley M, Lemay JF, Roy A, Gagnon HD, Jones MK, O'Shea R, Theiss R, Flett H, Guy K, Johnston G, Kokotow M, Mills S, Mokry J, Bain P, Scovil C, Houghton P, Lala D, Orr L, Holyoke P, Wolfe D, Orr L, Brooke J, Holyoke P, Lala D, Houghton P, Martin Ginis KA, Shaw RB, Stork MJ, McBride CB, Furlan JC, Craven BC, Giangregorio L, Hitzig S, Kapadia N, Popovic MR, Zivanovic V, Valiante T, Popovic MR, Patsakos E, Brisbois L, Farahani F, Kaiser A, Craven BC, Patsakos E, Kaiser A, Brisbois L, Farahani F, Craven BC, Mortenson B, MacGillivray M, Mahsa S, Adams J, Sawatzky B, Mills P, Arbour-Nicitopoulos K, Bassett-Gunter R, Leo J, Sharma R, Latimer-Cheung A, Olds T, Martin Ginis K, Graco M, Cross S, Thiyagarajan C, Shafazand S, Ayas N, Schembri R, Booker L, Nicholls C, Burns P, Nash M, Green S, Berlowitz DJ, Taran S, Rocchi M, Martin Ginis KA, Sweet SN, Caron JG, Sweet SN, Rocchi MA, Zelaya W, Sweet SN, Bergquist AJ, Del Castillo-Valenzuela MF, Popovic MR, Masani K, Ethans K, Casey A, Namaka M, Krassiokov-Enns D, Marquez-Chin C, Marquis A, Desai N, Zivanovic V, Hebert D, Popovic MR, Furlan JC, Craven BC, McLeod J, Hicks A, Gauthier C, Arel J, Brosseau R, Hicks AL, Gagnon DH, Nejatbakhsh N, Kaiser A, Hitzig SL, Cappe S, McGillivray C, Singh H, Sam J, Flett H, Craven BC, Verrier M, Musselman K, Koh RGL, Garai P, Zariffa J, Unger J, Oates AR, Arora T, Musselman K, Moshe B, Anthony B, Gulasingam S, Craven BC, Michalovic E, Gainforth HL, Baron J, Graham ID, Sweet SN, Chan B, Craven BC, Wodchis W, Cadarette S, Krahn M, Mittmann N, Chemtob K, Rocchi MA, Arbour-Nicitopoulos K, Kairy D, Sweet SN, Sabetian P, Koh RGL, Zariffa J, Yoo P, Iwasa SN, Babona-Pilipos R, Schneider P, Velayudhan P, Ahmed U, Popovic MR, Morshead CM, Yoo J, Shinya M, Milosevic M, Masani K, Gabison S, Mathur S, Nussbaum E, Popovic M, Verrier MC, Musselman K, Lemay JF, McCullum S, Guy K, Walden K, Zariffa J, Kalsi-Ryan S, Alizadeh-Meghrazi M, Lee J, Milligan J, Smith M, Athanasopoulos P, Jeji T, Howcroft J, Howcroft J, Townson A, Willms R, Plashkes T, Mills S, Flett H, Scovil C, Mazzella F, Morris H, Ventre A, Loh E, Guy S, Kramer J, Jeji T, Xia N, Mehta S, Martin Ginis KA, McBride CB, Shaw RB, West C, Ethans K, O'Connell C, Charlifue S, Gagnon DH, Escalona Castillo MJ, Vermette M, Carvalho LP, Karelis A, Kairy D, Aubertin-Leheudre M, Duclos C, Houghton PE, Orr L, Holyoke P, Kras-Dupuis A, Wolfe D, Munro B, Sweeny M, Craven BC, Flett H, Hitzig S, Farahani F, Alavinia SM, Omidvar M, Bayley M, Sweet SN, Gassaway J, Shaw R, Hong M, Everhart-Skeels S, Houlihan B, Burns A, Bilsky G, Lanig I, Graco M, Cross S, Thiyagarajan C, Shafazand S, Ayas N, Schembri R, Booker L, Nicholls C, Burns P, Nash M, Green S, Berlowitz D, Furlan JC, Kalsi-Ryan S.

J Spinal Cord Med. 2017 Nov;40(6):813-869. doi: 10.1080/10790268.2017.1369666. No abstract available.

PMID:
29034821
20.

Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases.

Tateiwa D, Outani H, Iwasa S, Imura Y, Tanaka T, Oshima K, Naka N, Araki N.

J Orthop Surg (Hong Kong). 2017 Sep-Dec;25(3):2309499017727916. doi: 10.1177/2309499017727916.

PMID:
28844196
21.

A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.

Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T.

Gastric Cancer. 2018 May;21(3):439-445. doi: 10.1007/s10120-017-0753-2. Epub 2017 Aug 1.

PMID:
28766263
22.

Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.

Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Umezawa R, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y.

Anticancer Res. 2017 Jul;37(7):3741-3749.

PMID:
28668869
23.

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature.

Watanabe S, Takashima A, Taniguchi H, Tanaka Y, Nakamura S, Okita N, Honma Y, Iwasa S, Kato K, Hamaguchi T, Boku N.

Case Rep Oncol. 2017 May 5;10(2):407-415. doi: 10.1159/000474939. eCollection 2017 May-Aug.

24.

Environmental Factors That Influence Stem Cell Migration: An "Electric Field".

Iwasa SN, Babona-Pilipos R, Morshead CM.

Stem Cells Int. 2017;2017:4276927. doi: 10.1155/2017/4276927. Epub 2017 May 15. Review.

25.

Enantioselective decarboxylative chlorination of β-ketocarboxylic acids.

Shibatomi K, Kitahara K, Sasaki N, Kawasaki Y, Fujisawa I, Iwasa S.

Nat Commun. 2017 Jun 5;8:15600. doi: 10.1038/ncomms15600.

26.

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Kitagawa Y.

Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15.

PMID:
28314688
27.

Ru(ii)-Pheox-catalyzed Si-H insertion reaction: construction of enantioenriched carbon and silicon centers.

Nakagawa Y, Chanthamath S, Fujisawa I, Shibatomi K, Iwasa S.

Chem Commun (Camb). 2017 Mar 28;53(26):3753-3756. doi: 10.1039/c7cc01070b.

PMID:
28304026
28.

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Shimomura A, Kondo S, Kobayashi N, Iwasa S, Kitano S, Tamura K, Fujiwara Y, Yamamoto N.

Int J Clin Oncol. 2017 Aug;22(4):780-785. doi: 10.1007/s10147-017-1108-z. Epub 2017 Mar 14.

29.

[Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer].

Ishimoto U, Nakamura S, Sasaki Y, Takahashi N, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Hamaguchi T, Boku N.

Gan To Kagaku Ryoho. 2017 Mar;44(3):233-237. Japanese.

PMID:
28292993
30.

Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.

Taniguchi H, Iwasa S, Yamazaki K, Yoshino T, Kiryu C, Naka Y, Liew EL, Sakata Y.

Cancer Sci. 2017 May;108(5):1013-1021. doi: 10.1111/cas.13227. Epub 2017 May 11.

31.

NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis.

Doi T, Hamaguchi T, Shitara K, Iwasa S, Shimada Y, Harada M, Naito K, Hayashi N, Masada A, Ohtsu A.

Cancer Chemother Pharmacol. 2017 Mar;79(3):569-578. doi: 10.1007/s00280-017-3254-4. Epub 2017 Feb 21.

32.

Immature Core protein of hepatitis C virus induces an unfolded protein response through inhibition of ERAD-L in a yeast model system.

Takahashi S, Sato N, Kikuchi J, Kakinuma H, Okawa J, Masuyama Y, Iwasa S, Irokawa H, Hwang GW, Naganuma A, Kohara M, Kuge S.

Genes Cells. 2017 Feb;22(2):160-173. doi: 10.1111/gtc.12464. Epub 2017 Jan 18.

33.

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.

Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y.

Invest New Drugs. 2017 Aug;35(4):451-462. doi: 10.1007/s10637-016-0416-x. Epub 2017 Jan 10.

34.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.

Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3.

35.

Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.

Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N.

Gastric Cancer. 2017 Jul;20(4):655-662. doi: 10.1007/s10120-016-0670-9. Epub 2016 Nov 17.

PMID:
27858180
36.

Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.

Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K.

Mol Cancer. 2016 Nov 16;15(1):73.

37.

Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.

Nomura M, Iwasa S, Tsushima T, Kato K, Yasui H, Boku N, Muto M, Muro K.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1209-1216. Epub 2016 Oct 24.

PMID:
27778070
38.

Enantioselective Cyclopropanation of a Wide Variety of Olefins Catalyzed by Ru(II)-Pheox Complexes.

Chanthamath S, Iwasa S.

Acc Chem Res. 2016 Oct 18;49(10):2080-2090. Epub 2016 Sep 20.

PMID:
27648664
39.

Functional expression of TLR5 in murine salivary gland epithelial cells.

Iwasa S, Ota H, Nishio K, Ohtsu M, Kusunoki M, Gojoubori T, Shirakawa T, Asano M.

J Oral Sci. 2016;58(3):317-23. doi: 10.2334/josnusd.15-0588.

40.

A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study).

Ohue M, Iwasa S, Kanemitsu Y, Hamaguchi T, Shiozawa M, Ito M, Yasui M, Katayama H, Mizusawa J, Shimada Y; Colorectal Cancer Study Group/Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2017 Jan;47(1):84-87. doi: 10.1093/jjco/hyw140. Epub 2016 Sep 21.

41.

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M.

Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27.

PMID:
27565810
42.

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).

Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T, Boku N, Yamada Y, Kodera Y, Yoshida K, Morita S, Sakamoto J, Saji S, Kitagawa Y.

Int J Cancer. 2017 Jan 1;140(1):188-196. doi: 10.1002/ijc.30383. Epub 2016 Oct 6.

43.

The Phospholipid:Diacylglycerol Acyltransferase Lro1 Is Responsible for Hepatitis C Virus Core-Induced Lipid Droplet Formation in a Yeast Model System.

Iwasa S, Sato N, Wang CW, Cheng YH, Irokawa H, Hwang GW, Naganuma A, Kuge S.

PLoS One. 2016 Jul 26;11(7):e0159324. doi: 10.1371/journal.pone.0159324. eCollection 2016.

44.

A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.

Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y.

Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. doi: 10.1007/s00280-016-3111-x. Epub 2016 Jul 20.

PMID:
27438067
45.

Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.

Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y.

Anticancer Res. 2016 Jul;36(7):3531-6.

PMID:
27354619
46.

Bileaflet mechanical valve replacement: an assessment of outcomes with 30 years of follow-up.

Saito S, Tsukui H, Iwasa S, Umehara N, Tomioka H, Aomi S, Yamazaki K.

Interact Cardiovasc Thorac Surg. 2016 Oct;23(4):599-607. doi: 10.1093/icvts/ivw196. Epub 2016 Jun 23.

PMID:
27341829
47.

Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.

Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, Kato K, Yamada Y, Hashimoto H, Taniguchi H, Kushima R, Nakao K, Boku N, Shimada Y.

Anticancer Drugs. 2016 Sep;27(8):794-9. doi: 10.1097/CAD.0000000000000393.

PMID:
27341105
48.

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N.

Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16.

PMID:
27312735
49.

Relationship of equol production between children aged 5-7 years and their mothers.

Wada K, Ueno T, Uchiyama S, Abiru Y, Tsuji M, Konishi K, Mizuta F, Goto Y, Tamura T, Shiraki M, Iwasa S, Nagata C.

Eur J Nutr. 2017 Aug;56(5):1911-1917. doi: 10.1007/s00394-016-1233-x. Epub 2016 Jun 2.

PMID:
27256298
50.

Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.

Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1727-38. doi: 10.1007/s00432-016-2184-6. Epub 2016 Jun 2.

PMID:
27256004

Supplemental Content

Support Center